Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.

ABSTRACT: A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune response to exposed N-terminal residues of the fusion peptide, a critical component of the viral entry machinery and the epitope of antibodies elicited by HIV-1 infection, through immunization with fusion peptide-coupled carriers and prefusion stabilized envelope trimers, induces cross-clade neutralizing responses. In mice, these immunogens elicited monoclonal antibodies capable of neutralizing up to 31% of a cross-clade panel of 208 HIV-1 strains. Crystal and cryoelectron microscopy structures of these antibodies revealed fusion peptide conformational diversity as a molecular explanation for the cross-clade neutralizatio

SUBMITTER: Xu K 

PROVIDER: S-EPMC6358635 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature